GSK OMB- OFATUMUMAB
Title: A phase 3 randomised study of Ofatumumab V’s Physicians choice in treatment of bulky Fludarabine refractory Chronic Lymphocytic Leukaemia (CLL)..
Population: Refractory to Fludarabine: Either no response to at least 2 cycles OR at least a Partial Response after 2 cycles lasting less than 6 months. Must have one Lymph Node >5cm.
Resource Links« Back